Intas Pharmaceuticals Limited — Epirubicin Exporter Profile
Indian Pharmaceutical Exporter · #5 for Epirubicin · $499.0K export value · DGFT Verified
Intas Pharmaceuticals Limited is the #5 Indian exporter of Epirubicin with $499.0K in export value and 72 verified shipments. Intas Pharmaceuticals Limited holds a 7.8% market share in Epirubicin exports across 10 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.
Intas Pharmaceuticals Limited — Epirubicin Export Profile: Buyers & Destinations
Where Does Intas Pharmaceuticals Limited Export Epirubicin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| SOUTH AFRICA | $249.7K | 14 | 54.7% |
| BRAZIL | $67.8K | 3 | 14.8% |
| GREECE | $53.1K | 3 | 11.6% |
| POLAND | $36.0K | 10 | 7.9% |
| UNITED KINGDOM | $23.4K | 6 | 5.1% |
| NETHERLANDS | $19.5K | 6 | 4.3% |
| AUSTRIA | $2.8K | 1 | 0.6% |
| MYANMAR | $1.6K | 2 | 0.4% |
| HUNGARY | $1.5K | 26 | 0.3% |
| SPAIN | $1.3K | 3 | 0.3% |
Intas Pharmaceuticals Limited exports Epirubicin to 10 countries. The largest destination is SOUTH AFRICA accounting for 54.7% of Intas Pharmaceuticals Limited's Epirubicin shipments, followed by BRAZIL (14.8%) and GREECE (11.6%). These destinations reflect Intas Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Epirubicin from Intas Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| ACCORD HEALTHCARE C/O QESTMED | SOUTH AFRICA | $243.3K | 12 |
| TO THE ORDER | HUNGARY | $69.9K | 8 |
| ACCORD FARMACEUTICA LIMITEDA | BRAZIL | $32.5K | 1 |
| ACCORD FARMACUTICA LIMITEDA | BRAZIL | $32.0K | 1 |
| ACCORD HEALTHCARE POLSKA SP. Z.O.O. | POLAND | $27.7K | 4 |
| ACCORD UK | UNITED KINGDOM | $23.4K | 6 |
| ACCORD HEALTHCARE POLSKA SP. Z O.O. | POLAND | $4.1K | 3 |
| ACCORD HEALTHCARE POLSKA SP ZOO MAGAZYN IMPORTERA UL LUTOMIERSKA | POLAND | $4.1K | 3 |
| ACCORD FARMACEUTICA LTDA | BRAZIL | $3.4K | 1 |
| PHARMA LOGISTIK AUSTRIA GMBH | AUSTRIA | $2.8K | 1 |
Intas Pharmaceuticals Limited supplies Epirubicin to 23 buyers globally. The largest buyer is ACCORD HEALTHCARE C/O QESTMED (SOUTH AFRICA), followed by TO THE ORDER (HUNGARY) and ACCORD FARMACEUTICA LIMITEDA (BRAZIL). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Epirubicin Export Value and How Much Does Intas Pharmaceuticals Limited Contribute?
India exported $5.5M worth of Epirubicin through 763 shipments from 156 suppliers to 92 countries, serving 296 buyers globally. Intas Pharmaceuticals Limited contributes $499.0K to this total, accounting for 7.8% of India's Epirubicin exports. Intas Pharmaceuticals Limited ships Epirubicin to 10 countries through 23 buyers.
What Is the Average Shipment Value for Intas Pharmaceuticals Limited's Epirubicin Exports?
Intas Pharmaceuticals Limited's average Epirubicin shipment value is $6.9K per consignment, based on 72 shipments totaling $499.0K. The largest destination is SOUTH AFRICA (54.7% of Intas Pharmaceuticals Limited's Epirubicin exports).
How Does Intas Pharmaceuticals Limited Compare to Other Indian Epirubicin Exporters?
Intas Pharmaceuticals Limited ranks #5 among 156 Indian Epirubicin exporters with a 7.8% market share. The top 3 exporters are MYLAN LABORATORIES LIMITED ($1.3M), VENUS REMEDIES LIMITED ($1.2M), FRESENIUS KABI ONCOLOGY LIMITED ($1.1M). Intas Pharmaceuticals Limited processed 72 shipments to 10 destination countries.
What Epirubicin Formulations Does Intas Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARMA DRUGS AND MEDI ACCORD EPIRUBICIN50MG (2MG/ML 25ML) 1V AS PER INV | $144.2K | 6 |
| PHARMA DRUGS AND MEDI EPICORD 50 EPIRUBICIN HCL 2MG/ML25ML1V AS PER INV | $81.1K | 4 |
| PHARMA DRUGS & MEDI: EPIRUBICINHCL2MG/ML25ML 6800X1X1VIAL | $50.0K | 1 |
| PHARMA DRUG&MED:EPIRUBICIN HCL INJ.2MG/ML-25ML EACH ML CONTAINS:EPIRUBICIN HYDROCHLORIDE PH.EUR.2.0MG SODIUM CHLORIDE PHVLS | $32.5K | 1 |
| PHARMA DRUG&MED:EPIRUBICIN HCL INJ. 2MG/ | $32.0K | 1 |
| PHARMA DRUGS & MEDI Epirubicin Accord, 2 | $25.1K | 2 |
| PHARMA DRUGS AND MEDI ACCORD EPIRUBICIN10 2MG/ML 5ML 1V SA AS PER INV | $19.7K | 3 |
| PHARMA DRUGS & MEDI: EPIRUBICINHCL2MG/ML,5 ML1x1(ACORD-NL) 2835X1X1VIAL | $12.6K | 1 |
| PHARMA DRUGS & MEDI EPIRUBICIN HCL 2MG/M | $12.0K | 2 |
| PHARMA DRUGS & MEDI: EPIRUBICIN HCL 2MG/ML5ML(ACCORD-UK) 1884X1X1VIALNOS | $5.7K | 1 |
Intas Pharmaceuticals Limited exports 53 distinct Epirubicin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMA DRUGS AND MEDI ACCORD EPIRUBICIN50MG (2MG/ML 25ML) 1V with 6 shipments worth $144.2K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Epirubicin to Key Markets
What Intas Pharmaceuticals Limited must comply with to export Epirubicin to its top destination countries
South Africa — SAHPRA
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Brazil — ANVISA
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Intas Pharmaceuticals Limited Compare to Nearest Epirubicin Exporters?
Exporters ranked immediately above and below #5 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 3 | FRESENIUS KABI ONCOLOGY LIMITED | $1.1M | 42 | 7 | $25.8K |
| 4 | NAPROD LIFE SCIENCES PRIVATE LIMITED | $870.1K | 23 | 10 | $37.8K |
| 5 | INTAS PHARMACEUTICALS LIMITED ★ | $499.0K | 72 | 10 | $6.9K |
| 6 | ADMAC LIFESCIENCES | $117.9K | 10 | 1 | $11.8K |
| 7 | GETWELL PHARMA INDIA PRIVATE LIMITED | $110.2K | 25 | 3 | $4.4K |
Intas Pharmaceuticals Limited ranks #5 among 156 Indian Epirubicin exporters. Average shipment value of $6.9K compared to the market average of $35.4K. The closest competitors by value are FRESENIUS KABI ONCOLOGY LIMITED and NAPROD LIFE SCIENCES PRIVATE LIMITED.
Which Indian Ports Ship Epirubicin Exports?
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 141 | 18.5% |
| SAHAR AIR CARGO ACC (INBOM4) | 127 | 16.6% |
| SAHAR AIR | 115 | 15.1% |
| DELHI AIR | 99 | 13.0% |
| Bombay Air | 36 | 4.7% |
| AHEMDABAD AIR | 31 | 4.1% |
| Delhi Air | 23 | 3.0% |
| AHEMDABAD AIR ACC (INAMD4) | 22 | 2.9% |
Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Epirubicin Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)
Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.
Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.
About Intas Pharmaceuticals Limited
Intas Pharmaceuticals Limited exports 75 products worth $372.3M. Beyond Epirubicin, top products include Ras, Mycophenolate, Tacrolimus, Apixaban, Ezetimibe. View the complete Intas Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Epirubicin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Epirubicin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Intas Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 74 individual customs records matching Intas Pharmaceuticals Limited exporting Epirubicin, covering 53 formulations to 10 countries via 23 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 92+ countries, 296+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Epirubicin Export Data from Intas Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Limited's Epirubicin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Intas Pharmaceuticals Limited
Full Company Profile →
75 products · $372.3M total trade · 19 categories
Epirubicin Stats
Company Overview
Top Products by Intas Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Epirubicin. For current shipment-level data, contact TransData Nexus.